Arrhythmias (Cardiovascular) - Drugs In Development, 2021
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Arrhythmias (Cardiovascular) - Drugs In Development, 2021
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.
An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Arrhythmias (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 11 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.
Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.
An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Arrhythmias (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 11 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.
Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Arrhythmias - Overview
Arrhythmias - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Arrhythmias - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Arrhythmias - Companies Involved in Therapeutics Development
Academic Pharmaceuticals Inc
Aetas Pharma Co Ltd
Cardurion Pharmaceuticals LLC
Cynata Therapeutics Ltd
Espero BioPharma Inc
Galectin Therapeutics Inc
Gilead Sciences Inc
LATITUDE Pharmaceuticals Inc
Les Laboratoires Servier SAS
LQT Therapeutics Inc
Nissan Chemical Corp
OMEICOS Therapeutics GmbH
Orion Corp
SignPath Pharma Inc
Stablix
Vera Therapeutics Inc
Arrhythmias - Drug Profiles
amiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Activate hERG1 for Arrhythmias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belapectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efsevin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins for Arrhythmias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KN-93 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MC-450 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTC-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Activate KCNH2 for Romano-Ward Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORM-10103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORM-11372 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Myocardial Infarction and Ventricular Arrhythmia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 for Arrhythmia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Arrhythmia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Arrhythmias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RyR2 for Heart Failure and Arrhythmias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block KCa3.1 for Arrhythmias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules To Inhibit SGK-1 for Long QT Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
soestelol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPP-4040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Arrhythmias - Dormant Projects
Arrhythmias - Discontinued Products
Arrhythmias - Product Development Milestones
Featured News & Press Releases
Oct 29, 2020: AnaBios and Orion publish scientific article describing novel cardiac compound
Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology
Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Arrhythmias, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Arrhythmias - Pipeline by Academic Pharmaceuticals Inc, 2021
Arrhythmias - Pipeline by Aetas Pharma Co Ltd, 2021
Arrhythmias - Pipeline by Cardurion Pharmaceuticals LLC, 2021
Arrhythmias - Pipeline by Cynata Therapeutics Ltd, 2021
Arrhythmias - Pipeline by Espero BioPharma Inc, 2021
Arrhythmias - Pipeline by Galectin Therapeutics Inc, 2021
Arrhythmias - Pipeline by Gilead Sciences Inc, 2021
Arrhythmias - Pipeline by LATITUDE Pharmaceuticals Inc, 2021
Arrhythmias - Pipeline by Les Laboratoires Servier SAS, 2021
Arrhythmias - Pipeline by LQT Therapeutics Inc, 2021
Arrhythmias - Pipeline by Nissan Chemical Corp, 2021
Arrhythmias - Pipeline by OMEICOS Therapeutics GmbH, 2021
Arrhythmias - Pipeline by Orion Corp, 2021
Arrhythmias - Pipeline by SignPath Pharma Inc, 2021
Arrhythmias - Pipeline by Stablix, 2021
Arrhythmias - Pipeline by Vera Therapeutics Inc, 2021
Arrhythmias - Dormant Projects, 2021
Arrhythmias - Dormant Projects, 2021 (Contd..1)
Arrhythmias - Discontinued Products, 2021
List Of Figures
Number of Products under Development for Arrhythmias, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
RELATED REPORTS
Tachycardia (Tachyarrhythmias) - Global Clinical Trials Review, H2, 2021
Tachycardia (Tachyarrhythmias) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Tachycardia (Tachyarrhythmias) - Global Clinical Trials Review, H2, 2021 provides an overview of Tachycardia (Tachyarrhythmias) Clinical trials scenario.
View ReportTachycardia (Tachyarrhythmias) - Global Clinical Trials Review, H1, 2021
Tachycardia (Tachyarrhythmias) - Global Clinical Trials Review, H1, 2021GlobalDatas clinical trial report, Tachycardia (Tachyarrhythmias) - Global Clinical Trials Review, H1, 2021 provides an overview of Tachycardia (Tachyarrhythmias) Clinical trials scenario.
View ReportPulmonary Embolism (Cardiovascular) - Drugs In Development, 2021
Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021, provides an overview of the
View ReportRestenosis (Cardiovascular) - Drugs In Development, 2021
Restenosis (Cardiovascular) - Drugs In Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Restenosis (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Restenosis (Cardiovascular)
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
